← Back to Home

Five Hengrui Cancer Drugs Receive Clinical Trial Authorization in China, Advancing HRS-2329 Combination Research

The newly authorized Phase Ib/II study will explore combination therapies for solid tumors involving KRAS G12D inhibitors and immunotherapy drugs; whether they can balance anticancer efficacy and tolerability remains to be answered in human trials.

By SURL BioNews

When bringing different cancer drugs into a single study, the key is to identify combinations that patients can tolerate and that may offer additional benefits. Hengrui Pharma announced on November 18 that five of its drugs had received clinical trial authorization from China’s National Medical Products Administration, advancing research into combination therapies centered on HRS-2329 for solid tumors. The announcement concerns authorization for the study; no patient efficacy results from this trial are available yet.

According to the company’s announcement filed with the Hong Kong Stock Exchange, these applications were accepted on August 14, 2026. The authorization covers an open-label, multicenter Phase Ib/II trial evaluating the safety, tolerability, and efficacy of HRS-2329 in combination with antitumor therapies. The drugs involved are HRS-2329, HRS-6093, a subcutaneous formulation of SHR-9839, HRS-4642, and adebrelimab. The announcement did not specify the combinations in each treatment arm, enrollment numbers, or the timeline for completion.

HRS-2329 is being developed for advanced solid tumors with RAS mutations or gene amplification. The company said the drug had shown antitumor activity in preclinical animal models, but animal experiments cannot directly predict treatment effects in humans. The upcoming early-stage clinical research must establish dosing and tolerability ranges for the combinations before preliminary efficacy signals can be interpreted.

The list also includes two inhibitors targeting KRAS G12D: HRS-6093 is an oral formulation, while HRS-4642 is a liposomal injection. Both target the same mutant protein but use different formulation designs. This provides different options for exploring combination therapies, but the current announcement does not compare their performance in humans and cannot establish which approach has an advantage.

The other two drugs involve antibody therapies. Adebrelimab targets PD-L1, helping restore the immune system’s response to tumors by blocking the PD-1/PD-L1 immune checkpoint pathway. The authorization for SHR-9839 covers its subcutaneous formulation, which the company says can simultaneously block two tumor-related signaling pathways, although the announcement did not name the targets. Whether these mechanisms can form effective combinations with HRS-2329 requires validation through clinical data.

A same-day report by Caiwen published via Sina Finance also confirmed the authorizations for these five drugs and the relevant subsidiaries, and listed cumulative research and development spending for each project. Approximately RMB 116 million had been invested in HRS-2329 and approximately RMB 1.37 billion in adebrelimab. The company’s announcement noted that the amounts were unaudited. These figures represent historical investment in the projects and cannot be treated as the budget for this trial or as an indication of its probability of success.

This development gives the new combination therapies regulatory authorization to enter clinical evaluation, but several hurdles remain before patient benefit can be demonstrated. The open-label design means that investigators and participants know which treatments are being used, while the announcement has yet to disclose the control arrangements or the full set of evaluation endpoints. Beyond tumor responses, subsequent assessments will need to examine adverse reactions, duration of effect, and patient characteristics to determine which combinations merit further development.

References

  1. marketscreener.com
  2. Jiangsu Hengrui Pharmaceuticals via HKEXnews
  3. Caiwen via Sina Finance